How much does it cost to produce eribulin mesylate (API and finished drug)?
Public sources do not provide a single, reliable “production cost per unit” for eribulin mesylate that can be directly converted into a price. Cost depends heavily on whether you mean the cost to make the active pharmaceutical ingredient (API) versus the finished dosage form, the contract manufacturing setup, batch size, yield, solvent and purification requirements, and regulatory/quality testing.
What is publicly knowable at a high level is that eribulin is manufactured as a complex chemotherapeutic API with multi-step synthesis and strict Good Manufacturing Practice (GMP) controls, which typically drives manufacturing cost above simpler small molecules. However, without specific disclosures from a manufacturer or audited cost model, an exact figure cannot be stated from the information provided.
Why production cost is hard to pin down for eribulin specifically
Even when companies give “manufacturing cost” internally, it is often not published because:
- API cost and formulation cost are tracked separately, and purchasers may buy different “ends” (API, bulk drug substance, or finished vials).
- Batch economics dominate. A small batch with lower yield costs much more per kg than a larger, optimized run.
- Regulatory compliance (validation batches, stability, sterility/particulate testing, reference standards) adds cost that varies by site and country.
What you can use instead of a direct production-cost number
If your goal is budgeting or understanding drivers of the market price, the most practical proxies are:
- Public reports of manufacturing capacity expansion or supply constraints for eribulin products (these often explain price changes more than raw cost).
- Cost breakdowns in quality/CMC sections of filings or procurement documents (where available), which usually still don’t yield a single all-in number.
- Review articles or industry analyses that discuss general cost drivers for complex oncology APIs, even if they do not give eribulin-specific unit costs.
If you need a cost estimate, what inputs would let someone compute it
To estimate an eribulin mesylate production cost, you typically need:
- Target output (e.g., kg of API per year) and batch size
- Route details (number of steps, key intermediates, overall yield)
- Raw material prices for starting materials and reagents, including solvents
- Costs for chromatography or crystallization purification (if used at scale)
- GMP overhead, QA release testing, stability program, packaging, and waste handling
- Site location (labor and compliance costs) and expected manufacturing uptime
If you tell me whether you want (1) API-only, (2) finished vial cost basis, and (3) the region/currency and quantity (per vial vs per kg), I can structure a reasonable costing model from the information you provide.
Are there public sources that state eribulin mesylate manufacturing costs?
There are sometimes disclosures through litigation, procurement tenders, or regulatory/financial materials, but they are not consistent or complete enough to quote a definitive “production cost” in a general answer. If you share the source you’re working from (a link, report name, or excerpt), I can help interpret what portion of cost it actually covers (API vs finished goods, direct materials vs fully burdened).
---
Sources
No sources were provided in your prompt, so I didn’t cite any.